{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:56:40Z","timestamp":1784249800404,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Thermal ablation (TA) is an established treatment for early HCC. There is a lack of data on the efficacy of repeated TA for recurrent HCC, resulting in uncertainty whether good oncologic outcomes can be obtained without performing orthotopic liver transplantation (OLTx). This study analyses outcomes after TA, with a special focus on repeat TA for recurrent HCC, either as a stand-alone therapy, or in relationship with OLTx.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from a prospectively registered database on interventions for HCC in a tertiary hepatobiliary centre was completed with follow-up until December 2020. Outcomes studied were rate of recurrence after primary TA and after its repeat interventions, the occurrence of untreatable recurrence, OS and DSS after primary and repeat TA, and complications after TA. In cohorts matched for confounders, OSS and DSS were compared after TA with and without the intention to perform OLTx.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After TA, 100 patients (56\u00b78%) developed recurrent HCC, of whom 76 (76\u00b70%) underwent up to four repeat interventions. During follow-up, 76\u00b77% of patients never developed a recurrence unamenable to repeat TA or OLTx. OS was comparable after primary TA and repeat TA. In matched cohorts, OS and DSS were comparable after TA with and without the intention to perform OLTx.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found TA to be an effective and repeatable therapy for primary and recurrent HCC. Most recurrences can be treated with curative intent. There are patients who do well with TA alone without ever undergoing OLTx.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p>\u2022 <jats:italic>Recurrent HCC after primary TA can often be treated effectively with repeat TA. Survival after repeat TA is comparable to primary TA<\/jats:italic>.<\/jats:p>\n                <jats:p>\u2022 <jats:italic>In matched cohorts, outcomes after TA with and without subsequent waitlisting for OLTx are comparable<\/jats:italic>.<\/jats:p>\n                <jats:p>\u2022 <jats:italic>There are patients who do well for many years with primary and repeat TA alone; some despite multiple recurrences.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-021-08515-3","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T13:03:27Z","timestamp":1644325407000},"page":"4168-4176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Outcomes after primary and repeat thermal ablation of hepatocellular carcinoma with or without liver transplantation"],"prefix":"10.1007","volume":"32","author":[{"given":"Christiaan M. C.","family":"Serbanescu-Kele Apor de Zal\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon J. S.","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aad P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Pieter","family":"Pennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert P.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"8515_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"8515_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1586\/17474124.2015.1028363","volume":"9","author":"MC Wallace","year":"2015","unstructured":"Wallace MC, Preen D, Jeffrey GP, Adams LA (2015) The evolving epidemiology of hepatocellular carcinoma: A global perspective. Expert Rev Gastroenterol Hepatol 9:765\u2013779. https:\/\/doi.org\/10.1586\/17474124.2015.1028363","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"8515_CR3","doi-asserted-by":"crossref","unstructured":"Crocetti L, Bargellini I, Cioni R (2017) Loco-regional treatment of HCC: Current status. Clin Radiol 72:626\u2013635. S0009-9260(17)30041-7 [pii]","DOI":"10.1016\/j.crad.2017.01.013"},{"key":"8515_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/JOP.2017.022996","volume":"13","author":"NE Rich","year":"2017","unstructured":"Rich NE, Yopp AC, Singal AG (2017) Medical management of hepatocellular carcinoma. J Oncol Pract 13:356\u2013364. https:\/\/doi.org\/10.1200\/JOP.2017.022996","journal-title":"J Oncol Pract"},{"key":"8515_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/hep.29485","volume":"67","author":"L Kulik","year":"2018","unstructured":"Kulik L, Heimbach JK, Zaiem F et al (2018) Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 67:381\u2013400. https:\/\/doi.org\/10.1002\/hep.29485","journal-title":"Hepatology"},{"key":"8515_CR6","unstructured":"Damaskos C, Kaskantamis A, Garmpis N et al (2019) Intensive care unit outcomes following orthotopic liver transplantation: Single-center experience and review of the literature. G Chir 40:463\u2013480. 9126 [pii]"},{"key":"8515_CR7","doi-asserted-by":"publisher","unstructured":"Pommergaard HC, Rostved AA, Adam R et al (2018) Locoregional treatments before liver transplantation for hepatocellular carcinoma: A study from the european liver transplant registry. Transpl Int. https:\/\/doi.org\/10.1111\/tri.13123","DOI":"10.1111\/tri.13123"},{"key":"8515_CR8","doi-asserted-by":"crossref","unstructured":"Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O (2018) Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol 68:783\u2013797. S0168-8278(17)32351-6 [pii]","DOI":"10.1016\/j.jhep.2017.10.004"},{"key":"8515_CR9","doi-asserted-by":"publisher","unstructured":"Bale R, Schullian P, Eberle G et al (2019) Stereotactic radiofrequency ablation of hepatocellular carcinoma: A histopathological study in explanted livers. Hepatology 70:840\u2013850. https:\/\/doi.org\/10.1002\/hep.30406","DOI":"10.1002\/hep.30406"},{"key":"8515_CR10","doi-asserted-by":"crossref","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-213. 00000658-200408000-00003 [pii]","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"issue":"10","key":"8515_CR11","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/liv.14238","volume":"39","author":"KP de Jong","year":"2019","unstructured":"de Jong KP, Ruiter SJS, Pennings JP (2019) Stereotactic image guided microwave ablation of HCC: A step forward and still a long way to go. Liver Int 39(10):1798\u20131800","journal-title":"Liver Int"},{"key":"8515_CR12","unstructured":"Ahmed M, Solbiati L, Brace CL et al (2014) Image-guided tumor ablation: Standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol 25:1691-705.e4. S1051-0443(14)00845-8 [pii]"},{"key":"8515_CR13","doi-asserted-by":"publisher","unstructured":"Wang X, Liang H, Lu Z (2020) Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol 29:344\u2013352. https:\/\/doi.org\/10.1080\/13645706.2019.1649286","DOI":"10.1080\/13645706.2019.1649286"},{"key":"8515_CR14","doi-asserted-by":"publisher","unstructured":"Wang Y, Liao Y, Liu W et al (2021) Surgical resection versus re-ablation for intrahepatic recurrent hepatocellular carcinoma after initial ablation therapy. Dig Surg 38:46\u201357. https:\/\/doi.org\/10.1159\/000511157","DOI":"10.1159\/000511157"},{"key":"8515_CR15","doi-asserted-by":"publisher","unstructured":"Facciorusso A, Serviddio G, Muscatiello N (2016) Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther 7:477\u2013489. https:\/\/doi.org\/10.4292\/wjgpt.v7.i4.477","DOI":"10.4292\/wjgpt.v7.i4.477"},{"key":"8515_CR16","doi-asserted-by":"publisher","first-page":"10389","DOI":"10.2147\/OTT.S224809","volume":"12","author":"WJ Zhao","year":"2019","unstructured":"Zhao WJ, Zhu GQ, Wu YM, Wang WW, Bai BL (2019) Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular carcinoma by cancer risk groups: Results of propensity score-weighted analysis. Onco Targets Ther 12:10389\u201310400. https:\/\/doi.org\/10.2147\/OTT.S224809","journal-title":"Onco Targets Ther"},{"key":"8515_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","volume":"252","author":"J Huang","year":"2010","unstructured":"Huang J, Yan L, Cheng Z et al (2010) A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the milan criteria. Ann Surg 252:903\u2013912. https:\/\/doi.org\/10.1097\/SLA.0b013e3181efc656","journal-title":"Ann Surg"},{"key":"8515_CR18","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1111\/hepr.12264","volume":"44","author":"H Iida","year":"2014","unstructured":"Iida H, Aihara T, Ikuta S, Yamanaka N (2014) Comparative study of percutaneous radiofrequency ablation and hepatic resection for small, poorly differentiated hepatocellular carcinomas. Hepatol Res 44:E156\u2013E162. https:\/\/doi.org\/10.1111\/hepr.12264","journal-title":"Hepatol Res"},{"key":"8515_CR19","doi-asserted-by":"crossref","unstructured":"Mohkam K, Dumont PN, Manichon AF et al (2018) No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cm. J Hepatol. S0168\u20138278(18)30057\u20136 [pii]","DOI":"10.1016\/j.jhep.2018.01.014"},{"key":"8515_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4174\/astr.2018.94.2.74","volume":"94","author":"HW Lee","year":"2018","unstructured":"Lee HW, Lee JM, Yoon JH et al (2018) A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res 94:74\u201382. https:\/\/doi.org\/10.4174\/astr.2018.94.2.74","journal-title":"Ann Surg Treat Res"},{"key":"8515_CR21","doi-asserted-by":"crossref","unstructured":"Doyle A, Gorgen A, Muaddi H et al (2019) Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3\u202fcm in potentially transplantable patients. J Hepatol 70:866-873. S0168-8278(19)30001-7 [pii]","DOI":"10.1016\/j.jhep.2018.12.027"},{"key":"8515_CR22","doi-asserted-by":"publisher","unstructured":"Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH (2019) Efficacy of hepatic resection vs. radiofrequency ablation for patients with very-early-stage or early-stage hepatocellular carcinoma: A population-based study with stratification by age and tumor size. Front Oncol 9:113. https:\/\/doi.org\/10.3389\/fonc.2019.00113","DOI":"10.3389\/fonc.2019.00113"},{"key":"8515_CR23","doi-asserted-by":"publisher","unstructured":"Yue YY, Zhou WL (2020) Hepatic resection is associated with improved long-term survival compared to radio-frequency ablation in patients with multifocal hepatocellular carcinoma. Front Oncol 10:110. https:\/\/doi.org\/10.3389\/fonc.2020.00110","DOI":"10.3389\/fonc.2020.00110"},{"key":"8515_CR24","doi-asserted-by":"crossref","unstructured":"Gui CH, Baey S, D'cruz RT, Shelat VG (2020) Trans-arterial chemoembolization + radiofre-quency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis. Eur J Surg Oncol 46:763-771. S0748-7983(20)30004-4 [pii]","DOI":"10.1016\/j.ejso.2020.01.004"},{"key":"8515_CR25","doi-asserted-by":"publisher","unstructured":"Sasaki K, Shindoh J, Margonis GA et al (2017) Effect of background liver cirrhosis on outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg 152:e165059. https:\/\/doi.org\/10.1001\/jamasurg.2016.5059","DOI":"10.1001\/jamasurg.2016.5059"},{"key":"8515_CR26","doi-asserted-by":"publisher","unstructured":"Yang A, Xiao W, Chen D et al (2018) The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients. Cancer Med 7:6040\u20136050. https:\/\/doi.org\/10.1002\/cam4.1873","DOI":"10.1002\/cam4.1873"},{"key":"8515_CR27","doi-asserted-by":"publisher","unstructured":"Kollmann D, Selzner N, Selzner M (2017) Bridging to liver transplantation in HCC patients. Langenbecks Arch Surg 402:863\u2013871. https:\/\/doi.org\/10.1007\/s00423-017-1609-2","DOI":"10.1007\/s00423-017-1609-2"},{"key":"8515_CR28","doi-asserted-by":"publisher","unstructured":"Tan CHN, Yu Y, Tan YRN et al (2018) Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere? Ann Hepatobiliary Pancreat Surg 22:27\u201335. https:\/\/doi.org\/10.14701\/ahbps.2018.22.1.27","DOI":"10.14701\/ahbps.2018.22.1.27"},{"key":"8515_CR29","doi-asserted-by":"crossref","unstructured":"Cucchetti A, Serenari M, Sposito C et al (2020) Including mRECIST in the metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol 73:342\u2013348. S0168-8278(20)30177-X [pii]","DOI":"10.1016\/j.jhep.2020.03.018"},{"key":"8515_CR30","doi-asserted-by":"publisher","unstructured":"Mehta N, Yao FY (2019) What are the optimal liver transplantation criteria for hepatocellular carcinoma? Clin Liver Dis (Hoboken) 13:20-25. https:\/\/doi.org\/10.1002\/cld.793","DOI":"10.1002\/cld.793"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-021-08515-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:20:51Z","timestamp":1653042051000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-021-08515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["8515"],"URL":"https:\/\/doi.org\/10.1007\/s00330-021-08515-3","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is K.P. de Jong, Hepato-Pancreato-Biliary surgeon, transplant surgeon, and head of the locoregional treatment team of the Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation at the University of Groningen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and Biometry"}},{"value":"Written informed consent was not required for this study because of its retrospective nature.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Institutional Review Board approval was not required because of the retrospective nature of our study..","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"\u2022 retrospective\u2022 observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}